CC BY-NC-ND 4.0 · Laryngorhinootologie 2021; 100(S 02): S260
DOI: 10.1055/s-0041-1728568
Abstracts
Phoniatrics

Use of electrical neuromodulation to control adductory spasmodic dysphonia (AdSD) symptoms

B Schneider-Stickler
1   Medizinische Universität Wien, Universitätsklinik für Hals-, Nasen- und Ohrenkrankheiten, Wien, Austria
,
M Leonhard
1   Medizinische Universität Wien, Universitätsklinik für Hals-, Nasen- und Ohrenkrankheiten, Wien, Austria
,
G-Y Ho
1   Medizinische Universität Wien, Universitätsklinik für Hals-, Nasen- und Ohrenkrankheiten, Wien, Austria
,
A-M Kuttenreich
2   Universitätsklinikum Jena, Klinik für Hals-, Nasen- und Ohrenheilkunde, Jena
,
G F Volk
3   Universitätsklinikum Jena, Fazialis-Nerv-Zentrum Jena, Jena
› Author Affiliations
› Further Information
Also available at
 
 

    Introduction Evidence has been published showing that the superior laryngeal nerve (SLN) paralysis can lead to significant pitch range contractions, vocal fold vibratory phase asymmetry, and acoustic aperiodicity, thus leading to an overall poor vocal quality, suggesting that this nerve may play a significant role in the development of spasmodic dysphonia (SD) symptoms. In 2014, initial results on the potential beneficial effects of unilateral electrostimulation of the thyroarytenoid muscle (TA) on the control of adductory SD (AdSD) were published. Our study aims to evaluate the effects of electrostimulation directly delivered to the internal branch of the SLN (iSLN) on the control of AdSD symptoms

    Method Percutaneous electrostimulation was delivered via hooked-wire electrodes 30 min per day for 5 consecutive days. Spasm count (SC), voice strain (VS), phonation effort (PE), voice range profile (VRP), Roughness, Breathiness, Hoarseness (RBH), Maximum Phonation Time (MPT), Voice Handicap Index 9 (VHI-9), and various Quality of Life (QoL) Questionnaires were assessed

    Results So far 6 patients (1 male, 5 female) have been enrolled to the study. PE, VS and SC (p=0.031) significantly improved after 5 days of stimulation compared with baseline. All the other assessed parameters showed an improvement, although not statistically significant, possible due to the limited sample size. No adverse event has been reported so far linked to the stimulation

    Conclusions Our initial results showed that the iSLN stimulation significantly reduce the SC, VS and PE of the treated patients without causing adverse events. The true effects of the treatment on the VRP and on the QoL will be reassessed in a larger sample size as soon as enough patients are recruited to the study

    Poster-PDF A-1364.pdf

    MED-EL Elektromedizinische Geräte GmbH


    #

    Conflict of interest

    Der Erstautor gibt keinen Interessenskonflikt an.

    Address for correspondence

    ao. Univ.-Prof. Dr. med.univ. Schneider-Stickler Berit
    Medizinische Universität Wien, Universitätsklinik für Hals-, Nasen- und Ohrenkrankheiten
    Wien
    Austria   

    Publication History

    Article published online:
    13 May 2021

    © 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

    Georg Thieme Verlag KG
    Rüdigerstraße 14, 70469 Stuttgart, Germany